AIMS: Diabetes is emerging as a risk factor for coronavirus disease (COVID)-19 prognosis. However, contradictory findings have been reported regarding the impact of glycaemic control on COVID-19 outcome. The aim of this meta-analysis was to explore the impact of hospital pre-admission or at-admission values of HbA1c on COVID-19 mortality or worsening in patients with diabetes. MATERIALS AND METHODS: We searched PubMed, Embase and Scopus up to 30th December 2020. Eligibility criteria for study selection were the following: (1)enrolling patients with any form of diabetes mellitus and hospitalized for COVID-19 and (2) reporting data regarding HbA1c values before infection or at hospital admission in relation to COVID-19 mortality or worsening. Descriptive statistics, HbA1c values, odds ratios (ORs) and hazard ratios were extracted from seven observational studies and generic inverse variance (random effects) of OR was used to estimate the effect of HbA1c on COVID-19 outcome. RESULTS: HbA1c was linearly associated with an increased COVID-19 mortality or worsening when considered as a continuous variable (OR 1.01 [1.01, 1.01]; p < 0.00001). Similarly, when analysing studies providing the number of events according to the degree of glycaemic control among various strata, a significantly increased risk was observed with poor glycaemic control (OR 1.15 [1.11, 1.19]; p < 0.00001), a result corroborated by sensitivity analysis. CONCLUSIONS: Notwithstanding the large heterogeneity in study design and patients' characteristics in the few available studies, data suggest that patients with diabetes and poor glycaemic control before infection might have an increased risk of COVID-19 related mortality.
AIMS: Diabetes is emerging as a risk factor for coronavirus disease (COVID)-19 prognosis. However, contradictory findings have been reported regarding the impact of glycaemic control on COVID-19 outcome. The aim of this meta-analysis was to explore the impact of hospital pre-admission or at-admission values of HbA1c on COVID-19 mortality or worsening in patients with diabetes. MATERIALS AND METHODS: We searched PubMed, Embase and Scopus up to 30th December 2020. Eligibility criteria for study selection were the following: (1)enrolling patients with any form of diabetes mellitus and hospitalized for COVID-19 and (2) reporting data regarding HbA1c values before infection or at hospital admission in relation to COVID-19 mortality or worsening. Descriptive statistics, HbA1c values, odds ratios (ORs) and hazard ratios were extracted from seven observational studies and generic inverse variance (random effects) of OR was used to estimate the effect of HbA1c on COVID-19 outcome. RESULTS: HbA1c was linearly associated with an increased COVID-19 mortality or worsening when considered as a continuous variable (OR 1.01 [1.01, 1.01]; p < 0.00001). Similarly, when analysing studies providing the number of events according to the degree of glycaemic control among various strata, a significantly increased risk was observed with poor glycaemic control (OR 1.15 [1.11, 1.19]; p < 0.00001), a result corroborated by sensitivity analysis. CONCLUSIONS: Notwithstanding the large heterogeneity in study design and patients' characteristics in the few available studies, data suggest that patients with diabetes and poor glycaemic control before infection might have an increased risk of COVID-19 related mortality.
Authors: Israel Pérez-Torres; María Elena Soto; Verónica Guarner-Lans; Linaloe Manzano-Pech; Elizabeth Soria-Castro Journal: Cells Date: 2022-06-21 Impact factor: 7.666
Authors: Rachel Wong; Margaret Hall; Rohith Vaddavalli; Adit Anand; Neha Arora; Carolyn T Bramante; Victor Garcia; Steven Johnson; Mary Saltz; Jena S Tronieri; Yun Jae Yoo; John B Buse; Joel Saltz; Joshua Miller; Richard Moffitt Journal: Diabetes Care Date: 2022-02-24 Impact factor: 17.152
Authors: Annalise E Zemlin; Brian Allwood; Rajiv T Erasmus; Tandi E Matsha; Zivanai C Chapanduka; Thumeka P Jalavu; Vera Ngah; Lovemore N Sigwadhi; Coenraad F Koegelenberg; Elvis Irusen; Usha Lalla; Anteneh Yalew; Nicola Baines; Jacques L Tamuzi; Anne K Barasa; Valerie Kemunto Magutu; Caroline Njeru; Angela Amayo; Marianne Wanjiru Mureithi; Mary Mungania; Musa Sono-Setati; Alimuddin Zumla; Peter S Nyasulu Journal: IJID Reg Date: 2022-01-23
Authors: Francesco Prattichizzo; Paola de Candia; Antonio Nicolucci; Antonio Ceriello Journal: Diabetes Metab Res Rev Date: 2021-05-28 Impact factor: 8.128
Authors: Sameh M Hozayen; Diana Zychowski; Sydney Benson; Pamela L Lutsey; Jasmin Haslbauer; Alexandar Tzankov; Zachary Kaltenborn; Michael Usher; Surbhi Shah; Christopher J Tignanelli; Ryan T Demmer Journal: EClinicalMedicine Date: 2021-09-24
Authors: Amna Alhakak; Jawad H Butt; Thomas A Gerds; Emil L Fosbøl; Ulrik M Mogensen; Johanna Krøll; Jannik L Pallisgaard; Gunnar H Gislason; Christian Torp-Pedersen; Lars Køber; Peter E Weeke Journal: Diabetes Obes Metab Date: 2021-12-05 Impact factor: 6.408
Authors: Celestino Sardu; Raffaele Marfella; Francesco Prattichizzo; Rosalba La Grotta; Giuseppe Paolisso; Antonio Ceriello Journal: J Clin Med Date: 2022-03-12 Impact factor: 4.241